WO1989010920A1 - Renin inhibitory peptides containing a substituted phenoxyacetyle group - Google Patents

Renin inhibitory peptides containing a substituted phenoxyacetyle group Download PDF

Info

Publication number
WO1989010920A1
WO1989010920A1 PCT/US1989/001672 US8901672W WO8910920A1 WO 1989010920 A1 WO1989010920 A1 WO 1989010920A1 US 8901672 W US8901672 W US 8901672W WO 8910920 A1 WO8910920 A1 WO 8910920A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ile
lva
amino
nhoch
Prior art date
Application number
PCT/US1989/001672
Other languages
French (fr)
Inventor
Heinrich J. Schostarez
Original Assignee
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company filed Critical The Upjohn Company
Publication of WO1989010920A1 publication Critical patent/WO1989010920A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Definitions

  • Renin inhibitory peptides containing a substituted phenoxyacetyl group Renin inhibitory peptides containing a substituted phenoxyacetyl group.
  • the present invention provides novel compounds. More particularly, the present invention provides novel peptide analogs.
  • the peptides of the present invention are useful as renin inhibitory peptides and contain a non-cleavable transition state insert corresponding to the 10, 11-position of the renin substrate (angiotensinogen) and a mono- or di-substituted phenoxyacetic acid moiety corresponding to the 8-position of the renin substrate. Renin inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, and other renin dependent cardiovascular disorders.
  • the peptides of the present invention are also useful as inhibitors of HIV-I protease. Inhibitors of HIV-I protease are useful for treating human acquired immunodeficiency disease syndrome (AIDS).
  • AIDS human acquired immunodeficiency disease syndrome
  • Renin is an endopeptidase which specifically cleaves a particular peptide bond of its substrate (angiotensinogen), of which the N-terminal sequence in equine substrate is for example:
  • Renin cleaves angiotensinogen to produce angiotensin I, which is converted to the potent pressor angiotensin II.
  • a number of angiotensin I converting enzyme inhibitors are known to be useful in the treatment of hypertension.
  • Inhibitors of renin are also useful in the treatment of hypertension.
  • Terminal disulfide cycles have also been disclosed in renin inhibiting peptides; see, e.g., U.S. patents 4,477,440 and 4,477,441.
  • Aromatic and aliphatic amino acid residues at the 10,11 position of the renin substrate are disclosed in U.S. patents 4,478,827 and 4,455,303.
  • C-terminal amide cycles are disclosed in U.S. patent 4,485,099 and European published applications 156,320 and 156,318.
  • Certain tetrapeptides are disclosed in European publications 111,266 and 77,027. Further, European published application No.
  • DE 3438545-A1 (an English-language equivalent is U.S. Patent 4,709,010) discloses 3-(2-,3-, or 4-substituted phenyl)-propionyl substituted peptides and unsubstituted-pheriyloxyacetyl substituted peptides having statine or analogs thereof as the transition state insert.
  • DE 3512128-A1 (an English-language equivalent is Australian Patent Application 55302/86) discloses 3- (2-, 3- or 4-substituted phenyl)-propionyl substituted peptides and unsubstituted-phenyloxyacetyl substituted peptides having two transition state inserts, amino-statine and statine, or analogs thereof. It also discloses unsubstituted-phenyloxyacetyl substituted peptides having statine or analogs thereof as the transition state insert and pyrrolidone at the C-terminus.
  • Phenoxyacetyl-His-LVA-Ile-NHOMe is generically disclosed and Phenoxyacetyl-His-LVA-Ile-Amp is specifically disclosed in European published application number 0173481.
  • the present invention particularly provides: A peptide of the formula I wherein Y is a moiety of the formula Y; wherein R 50 is
  • n is independently an integer of zero to five, inclusive; wherein p is zero to two, inclusive; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following .
  • -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following: (i) C 1 -C 6 alkyl,
  • the present invention provides peptide inhibitors of renin and
  • HIV-I protease which contain a mono- or di-substituted phenoxyacetic acid moiety.
  • This moiety is preferably at the N-terminus of the peptide.
  • the phenyl ring of this moiety is preferably substituted at the 2- or 3- position.
  • Examples of pharmaceutically acceptable acid addition salts include: acetate, adipate, alginate, aspartate, benzoate, ben zenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyan
  • the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix (C i -C j ) indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive.
  • (C 1 -C 4 )alkyl refers to alkyl of one to 4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl, and isomeric forms thereof.
  • C 4 -C 7 cyclic amino indicates a monocyclic group containing one nitrogen and 4 to 7 carbon atoms.
  • Examples of (C 3 -C 10 )cycloalkyl which include alkyl-substituted cycloalkyl containing a total of up to 10 total carbon atoms, are cyclopropyl, 2-methylcyclopropyl, 2.2-dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, 2-methylcyclobutyl, 3-propylcyclobutyl, cyclopentyl, 2,2-dimethylcyclopentyl, cyclohexyl, cycloheptyl. cyclooctyl, cyclononyl, cyclodecyl and isomeric forms thereof.
  • aryl examples include phenyl, naphthyl, (o-, m-, or p-)tolyl, (o-, m-, or p-)ethylphenyl, 2-ethyl-tolyl, 4-ethyl-o-tolyl, 5-ethyl-m-tolyl, (o-, m-, or p-)propylphenyl, 2-propyl-(o-, m-, or p-)tolyl, 4-isopropyl-2,6-xylyl, 3-propyl-4-ethylphenyl, (2,3,4-2,3,6-, or 2,4,5-)trimethylphenyl, (o-, m-, or p-)fluorophenyl, (o-, m-, or p-trifluoromethyl)phenyl, 4-fluoro-2,5-xylyl, (2,4-, 2,5-, 2,6-, 3,4-, or 3
  • Examples of -Het include: 2-, 3-, or 4-pyridyl, imidazolyl, indolyl, N in -formyl-indolyl, N in -C 1 -C 5 alkyl-C(0)-indolyl, 1,2,4-triazolyl, 2-, 4-, or 5-pyrimidinyl, 2- or 3-thienyl, piperidinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyrazinyl, piperazinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolldinyl, quinolin
  • a heterocycle as defined herein for -Het would not be bonded through oxygen or sulfur or through nitrogen which is within a ring and part of a double bond.
  • Halo is halogen (fluoro, chloro, bromo, or iodo) or trifluoromethyl.
  • Examples of pharmaceutically acceptable cations include: pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
  • pharmacologically acceptable metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are also within the scope of this invention.
  • Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines.
  • novel peptides herein contain both natural and synthetic amino acid residues. These residues are depicted using standard amino acid abbreviations (see, e.g., IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) , "Nomenclature and Symbolism for Amino Acids and Peptides," Eur. J. Biochem. 138:9-37 (1984) unless otherwise indicated.
  • JCBN IUPAC-IUB Joint Commission on Biochemical Nomenclature
  • the peptides of this invention are useful for treating any medical condition for which it is beneficial to reduce the levels of active circulating renin.
  • examples of such conditions include renindependent hypertension, hypertension, hypertension under treatment with another antihypertensive and/or a diuretic agent, congestive heart failure, renin-dependent hyperaldosterism, angina, post-myocardial Infarction, other renin-dependent cardiovascular disorders and ocular disorders.
  • the renin-a ⁇ giotension system may play a role in maintenance of intracellular homeostasis: see Clinical and Experimental Hypertension, 86, 1739-1742 (1984) at page 1740 under Discussion.
  • the peptides of the present invention are preferably orally administered to humans to effect renin inhibition for the purpose of favorably affecting blood pressure.
  • the compounds are administered from 0.1 mg to 1000 mg per kg per dose, administered from 1 to 4 times daily.
  • Equivalent dosages for other routes of administration are also employed.
  • renin-associated hypertension and hyperaldosteronism are effectively treated by the administration of from 0.5 to 100 milligrams of the compound per kilogram of body weight per day. The exact dose depends on the age, weight, and condition of the patient and on the frequency and route of administration. Such variations are within the skill of the practitioner or can readily be determined.
  • the peptides of the present invention to effect renin inhibition may be in the form of pharmaceutically acceptable salts both those which can be produced from the free bases by methods well known in the art and those with which acids have pharmacologically acceptable conjugate bases.
  • the peptides of the present invention to effect renin inhibition are preferably orally administered in the form of pharmacologically acceptable acid addition salts.
  • Preferred pharmacologically acceptable salts for oral administration include the citrate and aspartate salts, although any pharmacologically acceptable salt is useful in this invention, including those listed above. These salts may be in hydrated or solvated form.
  • the peptides of the present invention may be administered topically, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • the peptides of the invention are effective in the treatment of humans.
  • compositions of the peptides of the present invention for renin inhibition may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the peptides of this invention for renin inhibition may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • the peptides of this invention for renin inhibition may be administered in combination with other agents used in antihypertensive therapy such as diuretics, ⁇ and/or ⁇ -adrenergic blocking agents, CNS-acting agents, adrenergic neuron blocking agents, vasodilators, angiotensin I converting enzyme inhibitors, and the like as described for example in published European patent application 156,318.
  • agents used in antihypertensive therapy such as diuretics, ⁇ and/or ⁇ -adrenergic blocking agents, CNS-acting agents, adrenergic neuron blocking agents, vasodilators, angiotensin I converting enzyme inhibitors, and the like as described for example in published European patent application 156,318.
  • the peptides of this invention can be given in combination with such compounds or salt or other derivative forms thereof as: Diuretics: acetazolamide; amiloride; bendroflumethiazide; benzthiazide; bumetanide; chlorothiazide; chlorthalidone; cyclothiazide; ethacrynic acid; furosemide; hydrochlorothiazide; hydroflumethiazide; indacrinone (racemic mixture, or as either the (+) or (-) enantiomer alone, or a manipulated ratio, e.g., 9:1 of said enantiomers, respec tively); metolazone; methyclothiazide; muzolimine; polythiazide; quinethazone; sodium ethacrynate; sodium nitroprusside; spironolactone; ticrynaten; trimaterene; trichlormethiazide; ⁇ -
  • Other Antihypertensive Agents aminophylline; cryptenamine acetates and tannates; deserpidine; meremethoxylline procaine; pargyline; trimethaphan camsylate; and the like, as well as admixtures and combinations thereof.
  • the individual daily dosages for these combinations can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly.
  • Coadministration Is most readily accomplished by combining the active ingredients Into a suitable unit dosage form containing the proper dosages of each. Other methods of coadministration are, of course, possible.
  • novel peptides of the present invention possess an excellent degree of activity in treating renin-associated hypertension and hyperaldosteronism.
  • the peptides of the present invention are also useful as novel HIV-I protease inhibitory peptide analogues.
  • HIV human immunodeficiency virus
  • AIDS human acquired immunodeficiency disease syndrome
  • HIV-I protease a retro viral encoded protease
  • cleaves the fusion polypeptides into the functional proteins of the mature virus particle E.P. Lillehoj, et al., J. Virology, 62, 3053 (1988); C. Debuck, et al., Proc. Natl. Acad. Sci, 84, 8903 (1987).
  • HIV-I protease This enzyme, HIV-I protease, has been classified as an aspartyl protease and has a demonstrated homology to other aspartyl proteases such as renin, L.H. Pearl, et al., Nature, 329, 351 (1987); I. Katoh, et al., Nature, 329, 654 (1987). Inhibition of HIV-I protease blocks the replication of HIV and thus is useful in the treatment of human AIDS, E.D. Clerq, J. Med. Chem., 29, 1561 (1986). Inhibitors of HIV-I protease are useful in the treatment of AIDS.
  • Pepstatin A a general inhibitor of aspartyl proteases, has been disclosed as an inhibitor of HIV-I protease, S. Seelmeier, et al., proc. Natl. Acad. Sci. USA, 85, 6612 (1986).
  • Other substrate derived inhibitors containing reduced bond isosteres or statine at the scissle position have also been disclosed, M.L. Moore, et al., Biochem. Biophys. Res. Commun., 159, 420 (1989); S. Billich, et al., J. Biol. Chem., 263, 17905 (1988); Sandoz, D.E. 3812-576-A.
  • the peptides of the present invention are useful for treating human acquired immunodeficiency disease syndrome (AIDS), using dosages, forms and modes of administration equivalent to those described above. Exact dosages, forms and mode of administration would be apparent to one of ordinary skill in the art such as a physician or pharmacologist.
  • AIDS human acquired immunodeficiency disease syndrome
  • Chart A describes the preparation of the renin inhibitory peptides of the present invention.
  • X is chloro, fluoro, methyl, ethyl, isopropyl, methyloxy, or nitro.
  • the compound of formula A-1 is coupled with HCl ⁇ H 2 N-OCH 3 using triethylamine and diethylphosphoryl cyanide in methylene chloride to give the compound of formula A-2.
  • the compound of formula A-2 is first treated with trifluoroacetic acid in methylene chloride to remove the Boc- protecting group and then coupled with Boc-Leu ⁇ [CHO-TBS-CH 2 ]Val-OH using diethylphosphoryl cyanide and triethylamine to give the compound of formula A-3.
  • the compound of formula A-3 is first treated with trifluoroacetic acid in methylene chloride to remove the Boc- protecting group and then coupled with Boc-His(Tos)OH using diethylphosphoryl cyanide and triethylamine to give the compound of formula A-4.
  • the compound of formula A-4 is first treated with trifluoroacetic acid and methylene chloride to remove the Boc- protecting group and then coupled with X-POA-para-nitrophenyl ester (ONp) using dimethylformamide and triethylamine to give the compound of formula A-5.
  • the compound of formula A-5 is treated with sodium ethoxide in ethanol to remove the Tos- protecting group and to give the renin inhibitory peptide of formula A-6.
  • the compounds of the present invention wherein the phenoxyacetic acid moiety is disubstituted may be prepared by following procedures analogous to those described in Chart A.
  • Boc-His(Tos)-LVA(OTBS)-Ile-Amp which is an intermediate to some of the compounds of the present invention, is prepared as described in the following references: TenBririk, R.E.; Pals, D.T.; Harris, D.W.; Johnson, G.A., J. Med. Chem., 1988, 31:671; and Thaisrivongs, S.; Pals, D.T.; Harris, D.W.; Kati, W.M.; Turner, S.R., J. Med. Chem., 1986, 29:2088.
  • the renin inhibiting polypeptides may be prepared by either polymer assisted or solution phase peptide synthetic procedures analogous to those described hereinafter or to those methods known in the art.
  • Appropriate protecting groups, reagents, and solvents for both the solution and solid phase methods can be found in "The Peptides: Analysis, Synthesis, and Biology," Vols. 1-5, eds. E. Gross and T. Meienhofer, Academic Press, NY, 1979-1983; "Solid Phase Peptide Synthesis", J.M. Stewart and J.D. Young, Pierce Chemical Company, Rockford, 111., 1984; "The Practice of Peptide Synthesis", M. Bodansky and A.
  • the carboxylic moiety ofN ⁇ -t-butyloxycarbonyl (Boc)-substituted amino acid derivatives having suitable side chain protecting groups may be condensed with the amino functionality of a suitably protected amino acid, peptide or polymer-bound peptide using a conventional coupling protocol such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) or diethylphosphoryl cyanide (DEPC) and triethylamine (Et3N) in methylene chloride or dimethylformamide.
  • DCC dicyclohexylcarbodiimide
  • HOBT 1-hydroxybenzotriazole
  • DEPC diethylphosphoryl cyanide
  • Et3N triethylamine
  • N ⁇ -Boc moiety may be selectively removed with 50% trifluoroacetic acid with or without 2% anisole (v/v) in methylene chloride.
  • Neutralization of the resultant trifluoroacetate salt may be accomplished with 10% diisopropylethylamine or sodium bicarbonate in methylene chloride.
  • this stepwise, coupling strategy may be partially or completely automated to provide the desired peptide-polymer intermediates.
  • Protecting group removal may be accomplished while the peptide is bound to the polymeric support. Methanolysis or other cleavage methodologies known in the art may be used to cleave the peptide from its polymeric support.
  • N-alkylated compounds are known to an ordinarily skilled chemist or are readily available in the literature.
  • the compounds of the present invention may be in either free form or in protected form at one or more of the remaining (not previously protected) peptide, carboxyl, amino, hydroxy, or other reactive groups.
  • the protecting groups may be any of those known in the polypeptide art. Examples of nitrogen and oxygen protection groups are set forth in T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York, (1981); J.F.W. McOmie, ed. Protective Groups in Organic Chemistry, Plenum Press (1973); and J. Fuhrhop and G.
  • Benzlin Organic Synthesis, Verlag Chemie (1983). Included among the nitrogen protective groups are t-butoxycarbonyl (Boc), benzyloxycarbonyl, acetyl, allyl, phthalyl, benzyl, benzoyl, trityl and the like.
  • 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH 3 2-Methylphenoxyacetyl-His- LVA-Ile-Amp, 2-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH 3 , 3-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH 3 , 2-Ethylphenoxyacetyl-His-LVA-Ile-NHOCH 3 and 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH 3 .
  • the most preferred compounds are 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH 3 , 2-Methylphenoxyacetyl-His-LVA-Ile-Amp and 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH 3 .
  • CVA is Cha ⁇ [CH(OH)CH 2 ]Val
  • DCC is dicyclohexylcarbodiimide
  • DEPC diethylphosphoryl cyanide
  • EtOAc is ethyl acetate
  • FTrp is N in -formyl-Trp
  • g grams His is histldine
  • HOBT is 1-hydroxybenzotriazole
  • HPLC high performance liquid chromatography
  • Iba is isobutylamine
  • Ile is isoleucine
  • IR is infrared spectra
  • LVA is Leu ⁇ (CH(OH)CH 2 )Val with the S configuration at C4 (the hydroxyl-bearing carbon atom).
  • M or mol is mole
  • Me is methyl min is minute ml is milliliter
  • MPLC is medium pressure liquid chromatography
  • Ph is phenyl
  • Phe is phenylalanine RIP means a compound having the formula H-Pro-His-Phe-His-Phe-Phe-Val-Tyr-Lys-OH.2(CH 3 C(O)OH).XH 2 O which is a known renin-inhibiting peptide.
  • Sta is statine
  • TBS is tert-butyldimethylsilyl TEA is triethylamine
  • TFA is trifluoroacetic acid
  • THF is tetrahydrofuran
  • TLC is thin layer chromatography
  • Tos is p-toluenesulfonyl
  • TsOH is p-toluenesulfonic acid.
  • the wedge-shape line indicates a bond which extends above the plane of the paper relative to the plane of the compound thereon.
  • IR (mull, cm -1 ): 3327, 3117, 3081, 1785, 1594, 1522, 1349, 1160.
  • IR (mull, cm -1 ): 3113, 3079, 1778, 1526, 1509, 1345, 1176, 1170.
  • IR (mull, cm -1 ) 3326, 3077, 1785, 1522, 1492, 1348, 1208, 1122.
  • IR (mull, cm -1 ): 3084, 3018, 1767, 1531, 1344, 1208, 1159, 1131.
  • the solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-chlorophenoxyacetate of Preparation 15 (67 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 18 hr.
  • the solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe.
  • the solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated.
  • the solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-methylphenoxyacetate of Preparation 10 (110 mg) and additional triethylamine is added (0.035 ml), and the reaction stirred at room temperature for 66 hr.
  • the solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe.
  • the solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated.
  • Boc-His(Tos)-LVA(OTBS)-Ile-Amp which can be prepared by procedures known in the art, (149 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 0.5 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml).
  • Boc-CVA(0TBS)-0H (0.414 g), prepared as described in PTC patent application, Serial No. PCT/US89/00247, filed 27 January 1989, which is hereby incorporated by reference, additional triethylamine (0.24 ml), and diethylcyanophosphonate (0.260 ml) is added and the reaction mixture stirred at room temperature for 66 hours. The mixture is poured into saturated sodium bicarbonate solution and extracted 3 times with dichloromethane. Combined extracts are dried over anhydrous magnesium sulfate, filtered and concentrated.
  • the dimethylformamide is removed in vacuo, the residue resuspended in dry ethanol (2 ml) and sodium ethoxide (0.6 ml, 1M) is added via syringe.
  • the reaction mixture is stirred at room temperature for 3 hours, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass and concentrated.
  • the residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol saturated with gaseous ammonia in dichloromethane), to deliver the title product as a white solid. Physical characteristics are as follows: MS (FAB, m/z) 699 [M+H ]+ . Exact Mass found: 699.4440.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel peptides. These peptides are useful as renin inhibitors and have a non-cleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and a mono- or di-substituted phenoxyacetic acid moiety corresponding to the 8- position of the renin substrate. Renin inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin dependent cardiovascular disorders and ocular disorders. These peptides are also useful as inhibitors of HIV-I protease. Inhibitors of HIV-I protease are useful for treating human acquired immunodeficiency disease syndrome (AIDS).

Description

Renin inhibitory peptides containing a substituted phenoxyacetyl group.
DESCRIPTION BACKGROUND OF THE INVENTION The present invention provides novel compounds. More particularly, the present invention provides novel peptide analogs. The peptides of the present invention are useful as renin inhibitory peptides and contain a non-cleavable transition state insert corresponding to the 10, 11-position of the renin substrate (angiotensinogen) and a mono- or di-substituted phenoxyacetic acid moiety corresponding to the 8-position of the renin substrate. Renin inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, and other renin dependent cardiovascular disorders. The peptides of the present invention are also useful as inhibitors of HIV-I protease. Inhibitors of HIV-I protease are useful for treating human acquired immunodeficiency disease syndrome (AIDS).
Renin is an endopeptidase which specifically cleaves a particular peptide bond of its substrate (angiotensinogen), of which the N-terminal sequence in equine substrate is for example:
Renin ↓ Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser- IA
1 2 3 4 5 6 7 8 9 10 11 12 13 14
as found by L.T. Skeggs, et al., J. Exper. Med. 106, 439 (1957).
Human renin substrate has a different sequence as recently discovered by D.A. Tewkesbury, et al., Biochem. Biophys. Res. Comm. 99, 1311
(1981). It may be represented as follows: Renin ↓ -Val-Ile-His-
11 12 13 IB
and having the sequence to the left of the arrow (↓) being as designated in formula IA above.
Renin cleaves angiotensinogen to produce angiotensin I, which is converted to the potent pressor angiotensin II. A number of angiotensin I converting enzyme inhibitors are known to be useful in the treatment of hypertension. Inhibitors of renin are also useful in the treatment of hypertension.
A number of renin-inhibitory peptides have been disclosed. Thus, U.S. patent 4,424,207; European published applications 45,665; 104,041; and 156,322; and U.S. patent application, Serial No. 825,250, filed 3 February 1986; disclose certain peptides with the dipeptide at the 10,11-position containing an isostere bond. A number of statine derivatives stated to be renin inhibitors have been disclosed, see, e.g., European published applications 77,028; 81,783; 114,993; 156,319; and 156,321; and U.S. patents 4,478,826; 4,470,971; 4,479,941; and 4,485,099. Terminal disulfide cycles have also been disclosed in renin inhibiting peptides; see, e.g., U.S. patents 4,477,440 and 4,477,441. Aromatic and aliphatic amino acid residues at the 10,11 position of the renin substrate are disclosed in U.S. patents 4,478,827 and 4,455,303. C-terminal amide cycles are disclosed in U.S. patent 4,485,099 and European published applications 156,320 and 156,318. Certain tetrapeptides are disclosed in European publications 111,266 and 77,027. Further, European published application No. 118,223 discloses certain renin inhibiting peptide analogs where the 10-11 peptide link is replaced by a one to four atom carbon or carbon-nitrogen link. Additionally, Holladay, et al., in "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres", Tetrahedron Letters, Vol. 24, No. 41, pp. 4401-4404, 1983 disclose various intermediates in a process to prepare stereo-directed "ketomethylene" and "hydroxyethylene" dipeptide isosteric functional groups disclosed in the above noted U.S. Patent No. 4,424,207.
Additionally, published European Applications 45,161 and 53,017 disclose amide derivatives useful as inhibitors of angiotensin converting enzymes.
Certain dipeptide and tripeptides are disclosed in U.S. patents 4,514,332; 4,510,085; and 4,548,926 as well as in European published applications 128,762; 152,255; and 181,110. Pepstatin derived renin inhibitors have been disclosed in U.S. patent 4,481,192. Retroinverso bond modifications at positions 10-11 have been disclosed in U.S. patent 4,560,505 and in European published applications 127,234 and 127,235. Derivatives of isosteric bond replacements at positions 10-11 have been disclosed in European published applications 143,746 and 144,209; and U.S. patent application, Serial No. 833,993, filed 27 February 1986. Isosteric bond modifications at positions 11-12 and 12-13 have been disclosed in European published application 179,352. Certain peptides containing 2-substituted statine analogues have been disclosed in European published application 157,409. Certain peptides containing 3-aminodeoxystatine have been disclosed in European published application 161,588. Certain peptides containing l-amino-2-hydroxybutane derivatives at positions 10-11 have been disclosed in European published application 172 , 346. Certain peptides containing l-amino-2-hydroxypropane derivatives at positions 10-11 have been disclosed in European published application 172,347. Certain peptides containing N-terminal amide cycles have been disclosed in U.S. patent application, Serial No. 844,716, filed 27 March 1986. Certain peptides containing dihalostatine have been disclosed in PCT application, Serial No. 000,713, filed 7 April 1986.
European published applications 156,322; 114,993; and 118,223; and U.S. patent application, Serial No. 798,459, filed 15 November
1985; U.S. patent application, Serial No. 825,250, filed 3 February
1986; U.S. patent application, Serial No. 833,993, filed 27 February 1986; and U.S. patent application, Serial No. 844,716, filed 27 March 1986; disclose hydroxamic acids or esters at the C-terminus. INFORMATION DISCLOSURE
J. Boger, et al., Nature, Vol. 303, 5 May 1983, pages 81-84, discloses novel renin inhibitors containing the amino acid statine as the transition-state analog and containing unsubstituted phenoxyacetic acid as the N-terminal protecting group.
J. Boger, et al., "Peptides, Structure and Function, Proceedings of the Ninth American Peptide Symposium, " Deber, CM.; Hruby, V.J.; Kopple, K.D., Eds.; Pierce Chemical Co., Rockford, IL, 1985, pages 747-750, disclose renin inhibitors containing a novel analog of statine, such as (3S,4S)-4-amino-3-hydroxy-5-cyclohexylpentanoic acid as the transition-state analog and containing unsubstituted phenoxyacetic acid as the N-terminal protecting group.
DE 3438545-A1 (an English-language equivalent is U.S. Patent 4,709,010) discloses 3-(2-,3-, or 4-substituted phenyl)-propionyl substituted peptides and unsubstituted-pheriyloxyacetyl substituted peptides having statine or analogs thereof as the transition state insert. DE 3512128-A1 (an English-language equivalent is Australian Patent Application 55302/86) discloses 3- (2-, 3- or 4-substituted phenyl)-propionyl substituted peptides and unsubstituted-phenyloxyacetyl substituted peptides having two transition state inserts, amino-statine and statine, or analogs thereof. It also discloses unsubstituted-phenyloxyacetyl substituted peptides having statine or analogs thereof as the transition state insert and pyrrolidone at the C-terminus.
Phenoxyacetyl-His-LVA-Ile-NHOMe is generically disclosed and Phenoxyacetyl-His-LVA-Ile-Amp is specifically disclosed in European published application number 0173481.
SUMMARY OF THE INVENTION The present invention particularly provides: A peptide of the formula I wherein Y is a moiety of the formula Y; wherein R50 is
(a) chloro,
(b) fluoro,
(c) methyl, (d) ethyl,
(e) isopropyl,
(f) methyloxy, or
(g) nitro; wherein j is 1 or 2; wherein the phenyl ring of formula Y is mono-substituted by R50 at the 2- or 3-position or is disubstituted by R50 at the 2,3-position, 2,5-position, 2,6-position, 3,5-position or 3,6-position; provided that when the phenyl ring of formula Y is mono-substituted with methyl, R50 is 2-methyl; wherein D9 is a divalent moiety of the formula XL3; wherein E10 is a divalent moiety of the formula XL6; wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G12 is absent or a divalent moiety of the formula XL4; wherein H13 is absent; wherein I14 is absent; wherein Z is
(a) -N(R10) (OR14), (b) -O-R10,
(c) -N(R4)R14, or
(d) C4-C8cyclic amino; wherein R is (a) isopropyl,
(b) isobutyl,
(c) phenylmethyl, or
(d) -(CH2)p-C3-C7cycloalkyl; wherein R1 Is (a) hydrogen,
(b) C1-C5alkyl,
(c) aryl,
(d) C3-C7cycloalkyl,
(e) -Het, (f) C1-C3alkoxy, or
(g) C1-C3alkylthio; wherein R2 is
(a) hydrogen, or
(b) -CH(R3)R4; wherein R3 is
(a) hydrogen,
(b) hydroxy,
(c) C1-C5alkyl,
(d) C3-C7cycloalkyl, (e) aryl,
(f) -Het,
(g) C1-C3alkoxy, or (h) C1-C3alkylthio; wherein R4 at each occurrence is the same or different and is (a) hydrogen, or
(b) C1-C5alkyl; wherein R7 is
(a) hydrogen,
(b) C1-C5alkyl , (c) hydroxy,
(d) amino C1-C4alkyl- ,
(e) guanidinyl C1-C3alkyl- ,
(f) aryl , (g) -Het, (h) methylthio,
(i) -(CH2)p-C3-C7cycloalkyl, or
(j) amino; wherein R8 is
(a) hydrogen,
(b) C1-C5alkyl,
(c) hydroxy,
(d) aryl,
(e) -Het,
(f) guanidinyl-C1-C3alkyl-, or
(g) -(CH2)p-C3-C7cycloalkyl; wherein R10 is
(a) hydrogen, or
(b) Cχ-C5alkyl; wherein R11 is -R or -R2; wherein R14 Is
(a) C1-C10alkyl,
(b) -(CH2)n-aryl,
(c) -(CH2)n-Het,
(d) -(CH2)n+2-R18,
(e) -(CH2)n+2-R19,
(f) (hydroxy-C1-C8alkyl), or
(g) (C1-C3alkoxy)C1-C8alkyl; wherein R18 is
(a) amino,
(b) mono-, or di-C1-C3alkylamino,
(c) C4-C7cyclic amino, or
(d) C4-C7cycloalkylamino; wherein R19 is
(a) aryl,
(b) -Het,
(c) tri-C1-C3alkylamino,
(d) C3-C7cycloalkyl,
(e) C2-C5alkenyl,
(f) C3-C7cycloalkenyl,
(g) hydroxy,
(h) C1-C3alkoxy, (i) C1-C3alkanoyloxy,
(j) mercapto,
(k) C1-C3alkylthio,
(l) -COOH,
(m) -CO-O-C1-C6alkyl,
(n) -CO-O-CH2-(C1-C3alkyl)-N(C1-C3alkyl)2,
(o) -CO-NR22R25,
(p) guanidyl,
(q) cyano,
(r) N-cyanoguanidyl,
(s) cyanoamino,
(t) (hydroxy-C2-C4alkyl)amino,
(u) di-(hydroxy-C2-C4alkyl)amino, or
(v) SO3H wherein R22 is
(a) hydrogen, or
(b) C1-C3alkyl; wherein R25 is
(a) hydrogen,
(b) C1-C3alkyl, or
(c) phenyl-C1-C3alkyl; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to two, inclusive; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following .
(a) C1-C3alkyl,
(b) hydroxy,
(c) C1-C3alkoxy,
(d) halo,
(e) amino,
(f) mono- or di-C1-C3alkylamino,
(g) -CHO,
(h) -COOH,
(i) COOR25,
(j) CONHR25,
(k) nitro,
(l) mercapto, (m) C1-C3alkylthio, (n) C1-C3alleylsulfinyl, (o) C1-C3alkylsulfonyl, (p) -N(R4)-C1-C3alkylsulfonyl, (q) SO3H,
(r) SO2NH2, (s) -CN, or (t) -CH2NH2; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following: (i) C1-C6alkyl,
(ii) hydroxy, (iii) trifluoromethyl, (iv) C1-C4alkoxy, (v) halo, (vi) aryl,
(vii) aryl-C1-C4al-cyl-, (viii) amino, or
(ix) mono- or di-C1-C4alkylamino; or a carboxy-, amino-, or other reactive group-protected form thereof; or a pharmaceutically acceptable acid addition salt thereof. These compounds are shown in relation to the human renin substrate as follows:
6 7 8 9 10 11 12 13 -His Pro Phe His Leu Val Ile His-
X A6 B7 Cg D9 E10 FU G12 H13 I14 Z,
The present invention provides peptide inhibitors of renin and
HIV-I protease which contain a mono- or di-substituted phenoxyacetic acid moiety. This moiety is preferably at the N-terminus of the peptide. The phenyl ring of this moiety is preferably substituted at the 2- or 3- position.
Examples of pharmaceutically acceptable acid addition salts include: acetate, adipate, alginate, aspartate, benzoate, ben zenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix (Ci-Cj) indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus (C1-C4)alkyl refers to alkyl of one to 4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl, and isomeric forms thereof. C4-C7cyclic amino indicates a monocyclic group containing one nitrogen and 4 to 7 carbon atoms.
Examples of (C3-C10)cycloalkyl, which include alkyl-substituted cycloalkyl containing a total of up to 10 total carbon atoms, are cyclopropyl, 2-methylcyclopropyl, 2.2-dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, 2-methylcyclobutyl, 3-propylcyclobutyl, cyclopentyl, 2,2-dimethylcyclopentyl, cyclohexyl, cycloheptyl. cyclooctyl, cyclononyl, cyclodecyl and isomeric forms thereof.
Examples of aryl include phenyl, naphthyl, (o-, m-, or p-)tolyl, (o-, m-, or p-)ethylphenyl, 2-ethyl-tolyl, 4-ethyl-o-tolyl, 5-ethyl-m-tolyl, (o-, m-, or p-)propylphenyl, 2-propyl-(o-, m-, or p-)tolyl, 4-isopropyl-2,6-xylyl, 3-propyl-4-ethylphenyl, (2,3,4-2,3,6-, or 2,4,5-)trimethylphenyl, (o-, m-, or p-)fluorophenyl, (o-, m-, or p-trifluoromethyl)phenyl, 4-fluoro-2,5-xylyl, (2,4-, 2,5-, 2,6-, 3,4-, or 3 ,5-)difluorophenyl, (o-, m- , or p-)chlorophenyl, 2-chloro-p-tolyl, (3-, 4-, 5- or 6-)chloro-o-tolyl, 4-chloro-2-propylphenyl, 2-isopropyl-4-chlorophenyl, 4-chloro-3-fluorophenyl, (3- or 4-)chloro-2-fluorophenyl, (o-, m- , or p-)trifluoro-methylphenyl, (o-, m- , or p-)ethoxyphenyl, (4- or 5-)chloro-2-methoxy-phenyl, and 2,4-dichloro(5- or 6-)methylphenyl, and the like.
Examples of -Het include: 2-, 3-, or 4-pyridyl, imidazolyl, indolyl, Nin-formyl-indolyl, Nin-C1-C5alkyl-C(0)-indolyl, 1,2,4-triazolyl, 2-, 4-, or 5-pyrimidinyl, 2- or 3-thienyl, piperidinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyrazinyl, piperazinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolldinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, and benzothienyl. Each of these moieties may be substituted as noted above.
As would be generally recognized by those skilled in the art of organic chemistry, a heterocycle as defined herein for -Het would not be bonded through oxygen or sulfur or through nitrogen which is within a ring and part of a double bond.
Halo is halogen (fluoro, chloro, bromo, or iodo) or trifluoromethyl.
Examples of pharmaceutically acceptable cations include: pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations. Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are also within the scope of this invention. Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines.
The novel peptides herein contain both natural and synthetic amino acid residues. These residues are depicted using standard amino acid abbreviations (see, e.g., IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) , "Nomenclature and Symbolism for Amino Acids and Peptides," Eur. J. Biochem. 138:9-37 (1984) unless otherwise indicated.
The peptides of this invention are useful for treating any medical condition for which it is beneficial to reduce the levels of active circulating renin. Examples of such conditions include renindependent hypertension, hypertension, hypertension under treatment with another antihypertensive and/or a diuretic agent, congestive heart failure, renin-dependent hyperaldosterism, angina, post-myocardial Infarction, other renin-dependent cardiovascular disorders and ocular disorders. The renin-aπgiotension system may play a role in maintenance of intracellular homeostasis: see Clinical and Experimental Hypertension, 86, 1739-1742 (1984) at page 1740 under Discussion.
The peptides of the present invention are preferably orally administered to humans to effect renin inhibition for the purpose of favorably affecting blood pressure. For this purpose, the compounds are administered from 0.1 mg to 1000 mg per kg per dose, administered from 1 to 4 times daily. Equivalent dosages for other routes of administration are also employed. For example, renin-associated hypertension and hyperaldosteronism are effectively treated by the administration of from 0.5 to 100 milligrams of the compound per kilogram of body weight per day. The exact dose depends on the age, weight, and condition of the patient and on the frequency and route of administration. Such variations are within the skill of the practitioner or can readily be determined.
The peptides of the present invention to effect renin inhibition may be in the form of pharmaceutically acceptable salts both those which can be produced from the free bases by methods well known in the art and those with which acids have pharmacologically acceptable conjugate bases.
Conventional forms and means for administering renin- inhibiting compounds may be employed and are described, e.g., in U.S. Patent No. 4,424,207 which is incorporated by reference herein. Likewise, the amounts disclosed in the U.S. Patent No. 4,424,207 are examples applicable to the peptides of the present invention.
The peptides of the present invention to effect renin inhibition are preferably orally administered in the form of pharmacologically acceptable acid addition salts. Preferred pharmacologically acceptable salts for oral administration include the citrate and aspartate salts, although any pharmacologically acceptable salt is useful in this invention, including those listed above. These salts may be in hydrated or solvated form.
For renin inhibition, the peptides of the present invention may be administered topically, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs, cats, etc., the peptides of the invention are effective in the treatment of humans.
The pharmaceutical compositions of the peptides of the present invention for renin inhibition may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The peptides of this invention for renin inhibition may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
The peptides of this invention for renin inhibition may be administered in combination with other agents used in antihypertensive therapy such as diuretics, α and/or β-adrenergic blocking agents, CNS-acting agents, adrenergic neuron blocking agents, vasodilators, angiotensin I converting enzyme inhibitors, and the like as described for example in published European patent application 156,318.
For example, the peptides of this invention can be given in combination with such compounds or salt or other derivative forms thereof as: Diuretics: acetazolamide; amiloride; bendroflumethiazide; benzthiazide; bumetanide; chlorothiazide; chlorthalidone; cyclothiazide; ethacrynic acid; furosemide; hydrochlorothiazide; hydroflumethiazide; indacrinone (racemic mixture, or as either the (+) or (-) enantiomer alone, or a manipulated ratio, e.g., 9:1 of said enantiomers, respec tively); metolazone; methyclothiazide; muzolimine; polythiazide; quinethazone; sodium ethacrynate; sodium nitroprusside; spironolactone; ticrynaten; trimaterene; trichlormethiazide; α-Adrenergic Blocking Agents: dibenamine; phentolamine; phenoxybenzamine; prazosin; tolazoline; β-Adrenergic Blocking Agents: atenolol; metoprolol; nadolol; propranolol; timolol;
((±)-2-[3-(tert-butylamino)-2-hydroxypropoxy]-2-furananilide)
(ancarolol); (2-acetyl-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran HCl)(befunolol);
((±)-1-(isopropylamino)-3-(p-(2-cyclopropylmethoxyethyl)-phenoxy)-2-propranol HCl) (betaxolol);
(1-[(3,4-dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol HCl)(bevantolol);
(((±)-1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-isopropylamino-2-propanol)fumarate) (bisoprolol);
(4-(2-hydroxy-3-[4-(phenoxymethyl)-piperidino]-propoxy)-indole);
(carbazolyl-4-oxy-5,2-(2-methoxyphenoxy)-ethylamino-2-propanol); (1-((1,1-dimethylethyl)amino)-3-((2-methyl 'H-indol-4-yl)oxy)-2-propanol benzoate) (bopindolol);
(1-(2-exobicyclo[2.2.1]-hept-2-ylphenoxy)-3-[(1-methylethyl)-amino]- 2-propanol HCl) (bornaprolol);
(o-[2-hydroxy-3-[(2-indol-3-yl-1,1-dimethylethyl)-amino]propoxy]benzonitrile HCl) (bucindolol);
(α-[(tert.butylamino)methyl]-7-ethyl-2-benzofuranmethanol) (bufuralol);
(3-[3-acetyl-4-[3-(tert.butylamino)-2-hydroxypropyl]-phenyl]-1,1-diethylurea HCl) (celiprolol); ((±)-2-[2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenoxy]-N-methylacetamide HCl) (cetamolol);
(2-benzimidazolyl-phenyl(2-isopropylaminopropanol));
((±)-3'-acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide HCl) (diacetolol); (methyl-4-[2-hydroxy-3-[(1-methylethyl)aminopropoxyl]]-benzenepropanoate HCl) (esmolol);
(erythro-DL-1-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol);
(1-(tert.butylamino)-3-[0-(2-propynyloxy)phenoxy]-2-propanol (pargo lol) ;
(1-(tert.butylamino)-3-[o-(6-hydrazino-3-pyridazinyl)phenoxy]-2-propanol diHCl) (prizidilol);
((-)-2-hydroxy-5-[(R)-1-hydroxy-2-[(R)-(1-methyl-3-phenylpropyl)-amino]ethyl]benzamide);
(4-hydroxy-9-[2-hydroxy-3-(isopropylamino)-propoxy]-7-methyl-5H-furo[3,2-g][1]-benzopyran-5-one) (iprocrolol);
((-)-5-(tert.butylamino)-2-hydroxypropoxy]-3,4-dihydro-1-(2H)-naphthalenone HCl) (levobunolol); (4-(2-hydroxy-3-isopropylamino-propoxy)-1,2-benzisothiazole HCl);
(4-[3-(tert.butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril HCl);
((±)-N-2-[4-(2-hydroxy-3-isopropylaminopropoxy)phenyl]ethyl-N'-isopropylurea) (pafenolol); (3-[[(2-trifluoroacetamido)ethyl]amino]-1-phenoxypropan-2-ol);
(N-(3-(o-chlorophenoxy)-2-hydroxypropyl)-N'-(4'-chloro-2,3-dihydro-3-oxo-5-pyridazinyl)ethylenedlamine);
((±)-N-[3-acetyl-4-[2-hydroxy-3-[(l-methylethyl)amino]propoxyphenyl]-butanamlde) (acebutolol); ((±)-4'-[3-(tert-butylamino)-2-hydroxypropoxy]spiro[cyclohexane-1,2'- indan]-1'-one) (spirendolol);
(7-[3-[[2-hydroxy-3-[(2-methylindol-4-yl)oxylpropyl]amino]butyl]thiophylline) (teoprolol);
((±)-1-tert.butylamino-3-(thiochroman-8-yloxy)-2-propanol) (tertatolol);
((±)-1-tert.butylamino-3-(2,3-xylyloxy)-2-propanol HCl) (xibenolol); (8-[3-(tert.butylamino)-2-hydroxypropoxy]-5-methylcoumarin) (bucumolol);
(2-(3-(tert.butylamino)-2-hydroxy-propoxy)benzonitrile HCl) (bunitrolol);
((±)-2'-[3-(tert-butylamino)-2-hydroxypropoxy-5'-fluorobutyrophenone) (butofilolol);
(1-(carbazol-4-yloxy)-3-(isopropylamino)-2-propanol) (carazolol); (5-(3-tert.butylamino-2-hydroxy)propoxy-3,4-dihydrocarbotyril HCl) (carteolol);
(1-(tert.butylamino)-3-(2,5-dichlorophenoxy)-2-propanol) (cloranolol);
(1-(inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol HCl) (indeno lol);
(1-isopropylamino-3-[(2-methylindol-4-yl)oxy]-2-propanol) (mepindolol);
(1-(4-acetoxy-2,3,5-trimethylphenoxy)-3-isopropylaminopropan-2-ol) (metipranolol);
(1-(isopropylamino)-3-(o-methoxyphenoxy)-3-[(1-methylethyl)amino]-2-propanol) (moprolol);
((1-tert.butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol) (nadolol); ((S)-1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-2-propanol sulfate (2:1)) (penbutolol);
(4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide) (sotalol);
(2-methyl-3-[4-(2-hydroxy-3-tert.butylaminopropoxy)phenyl]-7-methoxyisoquinolin-1-(2H)-one); (1-(4-(2-(4-fluorophenyloxy)ethoxy)phenoxy)-3-isopropylamino-2-propanol HCl);
((-)-p-[3-[(3,4-dimethoxyphenethyl)amino]-2-hydroxypropoxy]-β-methylcinnamonitrile) (pacrinolol);
((±)-2-(3'-tert.butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole HCl) (arotinolol);
((±)-1-[p-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(isopropylamino)- 2-propanol) (cicloprolol);
((±)-1-[(3-chloro-2-methylindol-4-yl)oxy]-3-[(2-phenoxyethyl)amino]- 2-propanol) (indopanolol); ((±)-6-[[2-[[3-(p-butoxyphenoxy)-2-hydroxypropyl]amino]ethyl]amino]- 1,3-dimethyluracil) (pirepolol);
(4-(cyclohexylamino)-1-(1-naphtholenyloxy)-2-butanol);
(1-phenyl-3-[2-[3-(2-cyanophenoxy)-2-hydroxypropyl]aminoethyl]hydantoin HCl); (3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran) (nipradolol);
Angiotensin I Converting Enzyme Inhibitors:
1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline (captopril);
(1-(4-ethoxycarbonyl-2,4(R,R)-dimethylbutanoyl)indoline-2(S)-carboxylic acid);
(2-[2-[(1-(ethoxycarbonyl)-3-phenyl-propyl]amino]-1-oxopropyl]- 1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid);
((S)-1-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]oc tahydro-1H-indole-2-carboxylic acid HCl);
(N-cyclopentyl-N-(3-(2,2-dimethyl-1-oxopropyl)thiol-2-methyl-1-oxopropyl)glycine) (pivalopril);
((2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid);
(1-(N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl)-cis,syn-octahydroindol-2(S)-carboxylic acid HCl);
((-)-(S)-1-[(S)-3-mercapto-2-methyl-1-oxopropyl]indoline-2-carboxylic acid); ([1(S),4S]-1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-phenylthio-L-proline;
(3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1-acetic acid HCl);
(N-(2-benzyl-3-mercaptopropanoyl)-S-ethyl-L-cysteine) and the S-methyl analogue;
(N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline maleate) (enalapril);
N-[1-(S)-carboxy-3-phenylpropyl]-L-alanyl-1-proline; N2-[1-(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lysinopril); Other Antihypertensive Agents: aminophylline; cryptenamine acetates and tannates; deserpidine; meremethoxylline procaine; pargyline; trimethaphan camsylate; and the like, as well as admixtures and combinations thereof.
Typically, the individual daily dosages for these combinations can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly. Coadministration Is most readily accomplished by combining the active ingredients Into a suitable unit dosage form containing the proper dosages of each. Other methods of coadministration are, of course, possible.
Thus, the novel peptides of the present invention possess an excellent degree of activity in treating renin-associated hypertension and hyperaldosteronism.
The peptides of the present invention are also useful as novel HIV-I protease inhibitory peptide analogues.
It has been recognized that human immunodeficiency virus (HIV, also known as HTLV-III or LAV) is the causative agent in human acquired immunodeficiency disease syndrome (AIDS), P.Duesberg, Proc. Natl. Acad. Sci. USA, 86, 755 (1989). HIV contains a retro viral encoded protease, HIV-I protease, that cleaves the fusion polypeptides into the functional proteins of the mature virus particle, E.P. Lillehoj, et al., J. Virology, 62, 3053 (1988); C. Debuck, et al., Proc. Natl. Acad. Sci, 84, 8903 (1987). This enzyme, HIV-I protease, has been classified as an aspartyl protease and has a demonstrated homology to other aspartyl proteases such as renin, L.H. Pearl, et al., Nature, 329, 351 (1987); I. Katoh, et al., Nature, 329, 654 (1987). Inhibition of HIV-I protease blocks the replication of HIV and thus is useful in the treatment of human AIDS, E.D. Clerq, J. Med. Chem., 29, 1561 (1986). Inhibitors of HIV-I protease are useful in the treatment of AIDS.
Pepstatin A, a general inhibitor of aspartyl proteases, has been disclosed as an inhibitor of HIV-I protease, S. Seelmeier, et al., proc. Natl. Acad. Sci. USA, 85, 6612 (1986). Other substrate derived inhibitors containing reduced bond isosteres or statine at the scissle position have also been disclosed, M.L. Moore, et al., Biochem. Biophys. Res. Commun., 159, 420 (1989); S. Billich, et al., J. Biol. Chem., 263, 17905 (1988); Sandoz, D.E. 3812-576-A. Thus, the peptides of the present invention are useful for treating human acquired immunodeficiency disease syndrome (AIDS), using dosages, forms and modes of administration equivalent to those described above. Exact dosages, forms and mode of administration would be apparent to one of ordinary skill in the art such as a physician or pharmacologist.
The compounds of the present invention are prepared as depicted in the charts and as described more fully in the Preparations and Examples.
The process of the present invention is more completely understood by reference to the charts below. In these charts, the variables are as defined above.
CHART A Chart A describes the preparation of the renin inhibitory peptides of the present invention. In Chart A, X is chloro, fluoro, methyl, ethyl, isopropyl, methyloxy, or nitro.
The compound of formula A-1 is coupled with HCl·H2N-OCH3 using triethylamine and diethylphosphoryl cyanide in methylene chloride to give the compound of formula A-2. The compound of formula A-2 is first treated with trifluoroacetic acid in methylene chloride to remove the Boc- protecting group and then coupled with Boc-Leuψ[CHO-TBS-CH2]Val-OH using diethylphosphoryl cyanide and triethylamine to give the compound of formula A-3.
The compound of formula A-3 is first treated with trifluoroacetic acid in methylene chloride to remove the Boc- protecting group and then coupled with Boc-His(Tos)OH using diethylphosphoryl cyanide and triethylamine to give the compound of formula A-4. The compound of formula A-4 is first treated with trifluoroacetic acid and methylene chloride to remove the Boc- protecting group and then coupled with X-POA-para-nitrophenyl ester (ONp) using dimethylformamide and triethylamine to give the compound of formula A-5. The compound of formula A-5 is treated with sodium ethoxide in ethanol to remove the Tos- protecting group and to give the renin inhibitory peptide of formula A-6.
Using di-substituted-POA-ONp, the compounds of the present invention wherein the phenoxyacetic acid moiety is disubstituted may be prepared by following procedures analogous to those described in Chart A.
Boc-His(Tos)-LVA(OTBS)-Ile-Amp, which is an intermediate to some of the compounds of the present invention, is prepared as described in the following references: TenBririk, R.E.; Pals, D.T.; Harris, D.W.; Johnson, G.A., J. Med. Chem., 1988, 31:671; and Thaisrivongs, S.; Pals, D.T.; Harris, D.W.; Kati, W.M.; Turner, S.R., J. Med. Chem., 1986, 29:2088.
Generally, the renin inhibiting polypeptides may be prepared by either polymer assisted or solution phase peptide synthetic procedures analogous to those described hereinafter or to those methods known in the art. Appropriate protecting groups, reagents, and solvents for both the solution and solid phase methods can be found in "The Peptides: Analysis, Synthesis, and Biology," Vols. 1-5, eds. E. Gross and T. Meienhofer, Academic Press, NY, 1979-1983; "Solid Phase Peptide Synthesis", J.M. Stewart and J.D. Young, Pierce Chemical Company, Rockford, 111., 1984; "The Practice of Peptide Synthesis", M. Bodansky and A. Bodansky, Springer-Verlag, New York, 1984; "The Principles of Peptide Synthesis", M. Bodansky, Springer Verlag, New York, 1984. Thus, for example, the carboxylic moiety ofNα-t-butyloxycarbonyl (Boc)-substituted amino acid derivatives having suitable side chain protecting groups, if necessary, may be condensed with the amino functionality of a suitably protected amino acid, peptide or polymer-bound peptide using a conventional coupling protocol such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) or diethylphosphoryl cyanide (DEPC) and triethylamine (Et3N) in methylene chloride or dimethylformamide.
Following coupling reaction completion, the Nα-Boc moiety may be selectively removed with 50% trifluoroacetic acid with or without 2% anisole (v/v) in methylene chloride. Neutralization of the resultant trifluoroacetate salt may be accomplished with 10% diisopropylethylamine or sodium bicarbonate in methylene chloride. In the case of polymer-assisted peptide synthesis, this stepwise, coupling strategy may be partially or completely automated to provide the desired peptide-polymer intermediates.
Protecting group removal may be accomplished while the peptide is bound to the polymeric support. Methanolysis or other cleavage methodologies known in the art may be used to cleave the peptide from its polymeric support.
Variations in the above description for starting materials, reactants, reaction conditions and required protecting groups to obtain other such N-alkylated compounds are known to an ordinarily skilled chemist or are readily available in the literature. The compounds of the present invention may be in either free form or in protected form at one or more of the remaining (not previously protected) peptide, carboxyl, amino, hydroxy, or other reactive groups. The protecting groups may be any of those known in the polypeptide art. Examples of nitrogen and oxygen protection groups are set forth in T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York, (1981); J.F.W. McOmie, ed. Protective Groups in Organic Chemistry, Plenum Press (1973); and J. Fuhrhop and G. Benzlin, Organic Synthesis, Verlag Chemie (1983). Included among the nitrogen protective groups are t-butoxycarbonyl (Boc), benzyloxycarbonyl, acetyl, allyl, phthalyl, benzyl, benzoyl, trityl and the like.
The following compounds of the present invention are preferred: 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH3, 2-Methylphenoxyacetyl-His- LVA-Ile-Amp, 2-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3, 3-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3, 2-Ethylphenoxyacetyl-His-LVA-Ile-NHOCH3 and 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH3. The most preferred compounds are 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH3, 2-Methylphenoxyacetyl-His-LVA-Ile-Amp and 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH3.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The following Preparations and Examples illustrate the present invention. In the Preparations and Examples below and throughout this document: 1H-NMR is nuclear magnetic resonance Amp is 2-(aminomethyl)pyridinyl Bn is benzylester BOC is t-butoxycarbonyl Bz is benzyl C is centigrade Cbz is benzyloxycarbonyl CDCl3 is deuteriochloroform Celite is a filter aid
CVA is ChaΨ[CH(OH)CH2]Val DCC is dicyclohexylcarbodiimide DEPC is diethylphosphoryl cyanide EtOAc is ethyl acetate FTrp is Nin-formyl-Trp g is grams His is histldine HOBT is 1-hydroxybenzotriazole HPLC is high performance liquid chromatography Iba is isobutylamine Ile is isoleucine IR is infrared spectra
LVA is LeuτΨ(CH(OH)CH2)Val with the S configuration at C4 (the hydroxyl-bearing carbon atom). M or mol is mole Me is methyl min is minute ml is milliliter MPLC is medium pressure liquid chromatography MS is mass spectroscopy Ph is phenyl Phe is phenylalanine RIP means a compound having the formula H-Pro-His-Phe-His-Phe-Phe-Val-Tyr-Lys-OH.2(CH3C(O)OH).XH2O which is a known renin-inhibiting peptide.
Sta is statine
TBS is tert-butyldimethylsilyl TEA is triethylamine
TFA is trifluoroacetic acid THF is tetrahydrofuran TLC is thin layer chromatography Tos is p-toluenesulfonyl TsOH is p-toluenesulfonic acid.
The wedge-shape line indicates a bond which extends above the plane of the paper relative to the plane of the compound thereon.
The dotted line indicates a bond which extends below the plane of the paper relative to the plane of the compound thereon. Preparations 1-6 General Procedure for the Synthesis of Substituted Phenoxyacetic Acids A slurry of the requisite phenol, chloroacetic acid, and sodium hydroxide in water (100 ml) is refluxed in air for 4 hr, cooled to room temperature, and washed with diethyl ether. The aqueous layer is cooled to 0ºC, acidified to pH=2, and extracted with dichloromethane. The dichloromethane extracts are combined, dried with anhydrous magnesium sulfate, and concentrated. The resulting solid is recrystallized from ethyl acetate/hexane to give the desired purified acid. 1) Physical characteristics of 2-Fluorophenoxyacetic acid are as follows :
Yield: 1.97 g. Mp: 137-9°C.
MS (El, m/z): 170, 112, 125, 95. IR (mull, cm-1): 2807, 1736, 1712, 1504, 1431, 1260.
Anal. Found: C, 56.56; H, 4.16. 2) Physical characteristics of 3-Fluorophenoxyacetic acid are as follows : Yield: 2.18 g. Mp: 113-5°C.
MS (El, m/z): 44, 125, 170, 95, 94. IR (mull, cm-1): 1723, 1612, 1492, 1294, 1229. Anal. Found: C, 56.31; H, 4.30.
3) Physical characteristics of 2,6-Dimethylphenoxyacetic acid are as follows;
Yield: 3.7 g.
MS (El, m/z): 121, 180, 77, 91, 105. IR (mull, cm-1): 1732, 1710, 1263, 1199, 1066.
Anal. Found: C, 66.78; H, 7.04.
4) Physical characteristics of 2-Ethylphenoxyacetic acid are as follows:
Yield: 2.47 g. Mp: 137-9ºC.
MS (El, m/z): 121, 107, 180, 77, 91.
IR (mull, cm-1): 1740, 1706, 1496, 1426, 1240.
Anal. Found: C, 66.90; H, 6.93.
5) Physical characteristics of 2-Propylphenoxyacetic acid are as follows:
Yield: 2.62 g. Mp: 101-3ºC.
MS (El, m/z): 107, 165, 194, 91, 57. IR (mull, cm-1): 1741, 1706, 1498, 1239, 1136. Anal. Found: C, 68.22; H, 7.44.
6) Physical characteristics of 2-Isopropylphenoxyacetic acid are as follows:
Yield: 5.29 g. Mp: 131-3ºC. MS (El, m/z): 179, 133, 194, 105, 91.
IR (mull, cm-1): 1741, 1707, 1492, 1426, 1235. Anal. Found: C, 68.53; H, 7.20. Preparation 7 4-Nitrophenyl 3-Fluorophenoxyacetate
A slurry of 3-fluorophenoxyacetic acid of Preparation 2 (1.02 g) and 4-nitrophenol (0.84 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.38 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0°C for 40 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 1.14 g of the title product as a white solid. Physical characteristics are as follows:
MS (El, m/z): 125, 95, 97, 291, 152.
IR (mull, cm-1): 3327, 3117, 3081, 1785, 1594, 1522, 1349, 1160.
NMR (CDCl3, 5): 8.29, 7.33, 7.30-7.25, 6.78-6.69, 4.91. Preparation 8 4-Nitrophenyl 2-Fluorophenoxyacetate
A slurry of 2-fluorophenoxyacetic acid of Preparation 1 (1.08 g) and 4-nitrophenol (0.88 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.45 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0°C for 40 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 1.27 g of the title product as a white solid. Physical characteristics are as follows:
MS (El, m/z): 125, 95, 97, 291, 152.
IR (mull, cm-1): 3113, 3079, 1778, 1526, 1509, 1345, 1176, 1170.
NMR (CDCl3, 5): 8.28, 7.32, 7.18-7.00, 4.99. Preparation 9 4-Nitrophenyl 2,6-Dimethylphenoxyacetate
A slurry of 2,6-dimethylphenoxyacetic acid of Preparation 3 (1.03 g) and 4-nitrophenol (0.80 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.31 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0°C for 45 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 1.47 g of the title product as a white solid. Physical characteristics are as follows:
MS (El, m/z): 135, 105, 301, 77, 121.
IR (mull, cm-1): 3117, 3084, 1790, 1522, 1349, 1212, 1150, 1068. NMR (CDCl3, 5) : 8.31, 7.38, 7.07-6.96, 4.40, 2.36. Preparation 10 4-Nitrophenyl 2-Methylphenoxyacetate
A slurry of 2-methylphenoxyacetic acid, which is commercially available, (0.69 g) and 4-nitrophenol (0.58 g) in tetrahydrofuran (5 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (0.95 g) in tetrahydrofuran (5 ml) is added via syringe. The reaction mixture is stirred at 0ºC for 30 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow oil. Attempts to recrystallize the material were unsuccessful and the material was utilized in crude form. Preparation 11 4-Nitrophenyl 3-Methylphenoxyacetate
A slurry of 3-methylphenoxyacetic acid, which is commercially available, (0.78 g) and 4-nitrophenol (0.65 g) in tetrahydrofuran (5 ml) Is stirred at 0ºC and a solution of dicyclohexylcarbodiimide (1.10 g) in tetrahydrofuran (5 ml) Is added via sjrringe. The reaction mixture is stirred at 0ºC for 30 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. Attempts to recrystallize the material were unsuccessful and the material was utilized in crude form. Preparation 12 4-Nitrophenyl 2-Ethylphenoxyacetate
A slurry of 2-ethylphenoxyacetic acid of Preparation 4 (1.10 g) and 4-nitrophenol (0.85 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.40 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0ºC for 30 min, and allowed to warm to room temperature and stir for 72 hr. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 0.96 g of the title product as a white solid.
Physical characteristics are as follows: MS (El, m/z): 135, 56 , 99 , 55 , 105 , 310.
IR (mull, cm-1) : 3326, 3077, 1785, 1522, 1492, 1348, 1208, 1122.
NMR (CDCl3, O: 8.28, 7.31, 7.26-6.80, 4.94, 2.74, 1.24. Preparation 13 4-Nitrophenyl 2-Methoxyphenoxyacetate
A slurry of 2-methoxyphenoxyacetic acid, which is commercially available, (1.10 g) and 4-nitrophenol (0.84 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.34 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0°C for 30 min, and allowed to warm to room temperature and stir for 72 hr. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 1.03 g of the title product as a white solid. Physical characteristics are as follows: MS (El, m/z): 137, 122, 77, 303, 92.
IR (mull, cm-1): 3084, 3018, 1767, 1531, 1344, 1208, 1159, 1131.
NMR (CDCl3, 5): 8.27, 7.31, 7.07-6.90, 4.97, 3.91. Preparation 144-Nitrophenyl 2-Isopropylphenoxyacetate A slurry of 2-isopropylphenoxyacetic acid of Preparation 6 (1.14 g) and 4-nitrophenol (0.86 g) in tetrahydrofuran (15 ml) is stirred at 0ºC and a solution of dicyclohexylcarbodiimide (1.41 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0°C for 30 min, and allowed to warm to room temperature and stir overnight. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give 0.97 g of the title product as a white solid.
Physical characteristics are as follows: MS (EI, m/z): 315.
IR (mull, cm-1): 3395, 3038, 1786, 1711, 1524, 1450, 1351, 1142.
NMR (CDCl3, 5): 8.28, 7.32, 7.29-6.76, 4.94, 3.49-3.40, 1.26. Preparation 15 4-Nitrophenyl 2-Chlorophenoxyacetate A slurry of 2-chlorophenoxyacetic acid, which is commercially available, (0.61 g) and 4-nitrophenol (0.45 g) in tetrahydrofuran (10 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (0.74 g) in tetrahydrofuran (5 ml) is added via syringe. The reaction mixture is stirred at 0°C for 30 min, and allowed to warm to room temperature and stir for 72 hr. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give the title product as a white solid. Physical characteristics are as follows:
MS (El, m/z): 141, 111, 113, 143, 75, 307.
IR (mull, cm-1): 3117, 3086, 1771, 1521, 1485, 1346, 1205, 1155. NMR (CDCl3, 5): 8.28, 7.33, 7.44-6.96, 5.00. Preparation 164-Nitrophenyl 3-Chlorophenoxyacetate
A slurry of 3-chlorophenoxyacetic acid, which is commercially available, (0.56 g) and 4-nitrophenol (0.42 g) in tetrahydrofuran (10 ml) is stirred at 0ºC and a solution of dicyclohexylcarbodiimide (0.68 g) in tetrahydrofuran (5 ml) is added via syringe. The reaction mixture is stirred at 0°C for 30 min, and allowed to warm to room temperature and stir for 72 hr. The reaction mixture is filtered and the filtrate concentrated to give a yellow solid. The material is recrystallized from 95% ethanol/1% acetic acid to give the title product as a white solid.
Physical characteristics are as follows:
MS (El, m/z): 141, 111, 143, 113, 307.
IR (mull, cm-1): 3118, 3082, 1780, 1526, 1216, 1088.
NMR (CDCI3, δ): 8.29, 7.33, 7.30-6.86, 4.91. Preparation 17 Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3.
A. Boc-Ile-NHOCH3
A slurry of Boc-Ile-OH (2.66 g), O-methylhydroxylamine hydrochloride (1.16 g), and diethylphosphoryl cyanide (2.25 g) in dichloromethane (30 ml) is stirred at 0°C under argon and triethylamine (5.31 ml) added via syringe over a period of 5 min. The reaction mixture is stirred at 0°C for 1 hr and allowed to warm to room temperature and stir overnight. The reaction mixture is poured into water, extracted with ethyl acetate, washed with brine, dried (anhydrous sodium sulfate) and concentrated. The solid residue is recrystallized from diethyl ether to give the title intermediate (1.9 g) as a fluffy white solid.
Physical characteristics are as follows:
Mp 119-121°C.
[α]D 25 -37.5° (c 0.64, MeOH). IR (cm-1, mull) 3330, 3236, 1669, 1524, 1500.
MS (CI, isobutane, m/z) 205, 261 [M+H]+, 130, 262, 206.
Anal. Found: C.55.22; H.9.42; N.10.76.
B. Boc-LVA(OTBS)-Ile-NHOCH3 To a well stirred solution of the title intermediate of Part A (450 mg) in dichloromethane (5 ml) at room temperature is added trifluoroacetic acid (5 ml). The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dichloromethane. The solution is washed with saturated sodium bicarbonate solution, dried with anhydrous sodium sulfate, and concentrated. The residue is dissolved in dichloromethane (10 ml), Boc-LVA(OTBS)-OH (700 mg), triethylamine (1.0 ml), and diethylphosphoryl cyanide (0.32 ml) added and the reaction stirred at room temperature for 18 hr. The reaction mixture is diluted with dichloromethane, washed with water, saturated sodium bicarbonate solution, and brine. The organic layers are combined, dried with anhydrous sodium sulfate, and concentrated to give a residue which affords the title intermediate (600 mg) as an oil after chromatography on silica gel (elution with 25% ethyl acetate/hexane). Physical characteristics are as follows: MS (FAB, m/z) 584 [M+H]+. C. Boc-His(Tos)-LVA(0TBS)-Ile-NHOCH3
To a well stirred solution of the title intermediate of Part B (3.04 g) in dichloromethane (7 ml) at room temperature is added trifluoroacetic acid (7 ml) . The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dichloromethane (12 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), Boc-His(Tos)-OH (2.3 g), triethylamine (0.8 ml), and diethylphosphoryl cyanide (1.2 ml) added and the reaction stirred at room temperature for 24 hr. The solvent is removed in vacuo, the residue dissolved in ethyl acetate, washed with water, saturated sodium bicarbonate solution, and brine. The organic layers are combined, dried with anhydrous sodium sulfate, and concentrated to give a residue which affords the title product (1.99 g) as an oil after chromatography on silica gel (elution with 70% ethyl acetate/hexane).
Physical characteristics are as follows: MS (FAB, m/z) 893 [M+H]+.
Preparation 18 Boc-His(Tos)-LVA(OTBS)-Iba A. Boc-LVA(0TBS)-Iba
To a cold (0°C), well stirred solution of Boc-LVA(OTBS) -OH, prepared as described in European published application number 0173481, (1.0 g) in dichloromethane (10 ml) is added isobutylamine-(Iba) (241 mg), triethylamine (0.63 ml), and diethylphosphoryl cyanide (0.51 ml) via syringe. The reaction mixture is allowed to warm to room temperature and stir overnight. The reaction is poured into brine, extracted with dichloromethane, dried with anhydrous sodium sulfate and concentrated. Chromatography on silica gel (elution with 25% ethyl acetate/hexane) gives the title intermediate (1.0 g) as an oil. Physical characteristics are as follows:
% NMR (300MHz, CDCl3) δ 5.2, 4.43, 3.57, 3.11, 2.50, 1.98, 1.34, 1.60-1.20, 0.91-0.78, 0.80, 0.02, 0.01. B. Boc-His(Tos)-LVA(OTBS)-Iba
To a well stirred solution of the title intermediate of Part A (500 mg) in dichloromethane (5 ml) at room temperature is added trifluoroacetic acid (5 ml) . The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dichloromethane. The solution is washed with saturated sodium bicarbonate solution, dried with anhydrous sodium sulfate, and concentrated. The residue is dissolved in freshly distilled dichloromethane (10 ml), Boc-His(Tos)-OH (818 mg), triethylamine (0.55 ml), and diethylphosphoryl cyanide (0.32 ml) added and the reaction stirred at room temperature for 18 hr. The solvent is removed in vacuo, the residue dissolved in ethyl acetate, washed with water, saturated sodium bicarbonate solution, and brine. The organic layers are combined, dried with anhydrous sodium sulfate, and concentrated to give a residue which affords the title product (452 mg) as an oil after chromatography on silica gel (elution with 2.5% methanol/dichloromethane). Physical characteristics are as follows: MS (FAB, m/z) 792 [M+H]+. Example 1 2,6-Dimethylphenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A-6: X is 2, 6-dimethyl) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (152 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2,6-dimethylphenoxyacetate of Preparation 9 (65 mg) and additional triethylamine is added (0.025 ml) and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 3 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 110 mg of the title product as an amorphous solid. Physical characteristics are as follows: MS (FAB, m/z): 673. Exact Mass Found: 673.4293. Example 2 2-Chlorophenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A- 6: X is 2-chloro) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (157 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-chlorophenoxyacetate of Preparation 15 (67 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 18 hr. The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver the title product as an amorphous solid. Physical characteristics are as follows: MS (FAB, m/z): 679. Exact Mass Found: 679.3617. Example 3 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A-6: X is 2-methyl) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (217 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 2 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2.5 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-methylphenoxyacetate of Preparation 10 (110 mg) and additional triethylamine is added (0.035 ml), and the reaction stirred at room temperature for 66 hr. The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver the title product as an amorphous solid. Physical characteristics are as follows: MS (FAB, m/z): 659. Exact Mass Found: 679.4175.
Example 4 2-Methoxyphenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A- 6: X is 2-methoxy) Refer to Chart A.
To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (169 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1.5 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine
(monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-methoxyphenoxyacetate of Preparation 13 (70 mg) and additional triethylamine is added (0.027 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 43 mg of the title product as an amorphous solid.
Physical characteristics are as follows: MS (FAB, m/z): 675.
Exact Mass Found: 675.4083. Example 5 2-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A-6: X is 2-fluoro) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (158 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 2.5 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-fluorophenoxyacetate of Preparation 8 (65 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 66 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 4 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver the title product as an amorphous solid. Physical characteristics are as follows: MS (FAB, m/z): 663. Exact Mass Found: 663.3896. Example 6 2-Ethylphenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A-6:
X is 2-ethyl) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (157 mg) in dichloromethane (2 ml) at room tempera ture is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1.5 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-ethylphenoxyacetate of Preparation 12 (65 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 8% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver the title product as an amorphous solid. Physical characteristics are as follows: MS (FAB, m/z): 673. Exact Mass Found: 673.4326. Example 7 2-Isopropylphenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula
A-6: X is 2-isopropyl) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (160 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-isopropylphenoxyacetate of Preparation 14 (69 mg) and additional triethylamine is added (0.026 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 66 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merckk Lobar B, elution with 8% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 66 mg of the title product as an amorphous solid.
Physical characteristics are as follows:
MS (FAB, m/z): 687. Exact Mass Found: 687.4454.
Example 8 2-Methylphenoxyacetyl-His-LVA-Ile-Amp
To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-Amp, which can be prepared by procedures known in the art, (149 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 0.5 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-methylphenoxyacetate of Preparation 10 (62 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 2 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 6% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 22 mg of the title product as an amorphous solid.
Physical characteristics are as follows:
MS (FAB, m/z): 720.
Exact Mass Found: 720.4435. Example 9 3-Chlorophenoxyacetyl-His-LVA-Ile-NHOCH3 (Formula A-6: X is 3-chloro) Refer to Chart A.
To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (162 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 1 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 3-chlorophenoxyacetate of Preparation 16 (66 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 1 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 114 mg of the title product as an amorphous solid.
Physical characteristics are as follows: MS (FAB, m/z): 679. Exact mass Found: 679.3598. Example 10 3-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3
(Formula A-6: X is 3-fluoro) Refer to Chart A. To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Ile-NHOCH3 of Preparation 17 (163 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 3 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 3-fluorophenoxyacetate of Preparation 7 (66 mg) and additional triethylamine is added (0.025 ml), and the reaction stirred at room temperature for 66 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 4.5 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 38 mg of the title product as an amorphous solid.
Physical characteristics are as follows: MS (FAB, m/z): 66-3 [M+H]+. Exact Mass Found: 663.3863. Example 11 2-Methylphenoxyacetyl-His-LVA-Iba
To a well stirred solution of Boc-His(Tos)-LVA(OTBS)-Iba of Preparation 18 (197 mg) in dichloromethane (2 ml) at room temperature is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 2 hr, the solvents removed in vacuo, and the residue redissolved in dimethylformamide (2 ml). The solution is neutralized by the dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent), 4-nitrophenyl 2-methylphenoxyacetate of Preparation 10 (87 mg) and additional triethylamine is added (0.035 ml), and the reaction stirred at room temperature for 18 hr.
The solvent is removed in vacuo, the residue suspended in dry ethanol (2 ml) at room temperature, and sodium ethoxide (1M) is added via syringe. The solution is stirred at room temperature for 18 hr, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass, and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 5% methanol (saturated with gaseous ammonia)/- dichloromethane) to deliver 19 mg of the title product as an amorphous solid.
Physical characteristics are as follows: MS (FAB, m/z): 572 [M+H]+. Exact Mass Found: 572.3806. Preparation 19 Boc-CVA(OTBS)-Ile-NHOCH3 To a well stirred solution of Boc-Ile-NHOCH3 in dichloromethane (2 ml) is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for 2 hours, the solvents removed in vacuo and the residue redissolved in dichloromethane (5.3 ml). The solution is neutralized by dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Regent). Boc-CVA(0TBS)-0H (0.414 g), prepared as described in PTC patent application, Serial No. PCT/US89/00247, filed 27 January 1989, which is hereby incorporated by reference, additional triethylamine (0.24 ml), and diethylcyanophosphonate (0.260 ml) is added and the reaction mixture stirred at room temperature for 66 hours. The mixture is poured into saturated sodium bicarbonate solution and extracted 3 times with dichloromethane. Combined extracts are dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 40% ethyl acetate in hexane) , to yield the title product (0.515 g) as a white solid. Physical characteristics are as follows: MS (FAB, m/z) 628 [M+H]+, 73, 57, 86, 528, 75. Preparation 20 Boc-His(Tos)-CVA(OTBS)-Ile-NHOCH3
To a well stirred solution of the title product of Preparation 19 (0.509 g) in dichloromethane (2.5 ml) is added trifluoroacetic acid (2.5 ml). The reaction mixture is stirred at room temperature for 0.75 hour, the solvents removed in vacuo and the residue redissolved in dichloromethane (8 ml). The solution is neutralized by dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent). Boc-His(Tos)-OH (0.663 g), additional triethylamine (0.225 ml) and diethylcyanophosphonate (0.245 ml) is added and the reaction mixture stirred at room temperature for 4 days. Saturated sodium bicarbonate solution (2 ml) is added. The mixture is stirred vigorously for five minutes, transferred to a separatory funnel and extracted twice with dichloromethane. Combined extracts are dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 70% ethyl acetate in hexane) to yield the title product (0.573 g) as a solid.
Physical characteristics are as follows: MS (FAB, m/z) 919 [M+H]+, 110, 264, 919, 765, 73. Preparation 21 4-Nitrophenyl-2-methylphenoxyacetate A slurry of 2-methylphenoxyacetic acid (1.12 g) and 4-nitrophenol (0.951 g) in tetrahydrofuran (15 ml) is stirred at 0°C and a solution of dicyclohexylcarbodiimide (1.54 g) in tetrahydrofuran (10 ml) is added via syringe. The reaction mixture is stirred at 0ºC for one hour followed by room temperature overnight. The reaction mixture is filtered and the filtrate concentrated to yield a yellow oil. The crude product is crystallized from 95% ethanol/1% acetic acid to yield the title product (0.790 g) as an off-white solid. Physical characteristics are as follows: MS (El, m/z) 121, 91, 287, 65, 122. NMR (300 MHz, CDCl3) δ 8.27, 7.31, 7.21-7.16, 6.95, 6.81, 4.94, 2.32.
IR (mull, cm-1) 3328, 1769, 1527, 1497, 1346, 1208, 1167, 1131, 1077. Example 12 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH3 or 1-H- Imidazole-4-propanamide, N-[1-(cyclohexylmethyl)-2- hydroxy-4-[[[1-[(methoxyamino)carbonyl]-2-methylbutyl]amino]carbonyl]-5-methylhexyl]-α- [ [(2-methylphenoxy)acetyl]amino]-, [1S-[1R*(R*),2R*,4R*]]-
To a well stirred solution of the title product of Preparation 20 (0.268 g) in dichloromethane (2 ml) is added trifluoroacetic acid (2 ml). The reaction mixture is stirred at room temperature for one hour, the solvents removed in vacuo and the residue redissolved in dimethylformamide (3 ml). The solution is neutralized by dropwise addition of triethylamine (monitored with Fisher's Universal Indicating Reagent). The title product of Preparation 21 (0.146 g) and additional triethylamine (0.040 ml) are added and the reaction mixture is stirred at room temperature for 20 hours. The dimethylformamide is removed in vacuo, the residue resuspended in dry ethanol (2 ml) and sodium ethoxide (0.6 ml, 1M) is added via syringe. The reaction mixture is stirred at room temperature for 3 hours, neutralized with glacial acetic acid (monitored with Fisher's Universal Indicating Reagent), filtered through scintered glass and concentrated. The residue is chromatographed on silica gel (Merck Lobar B, elution with 10% methanol saturated with gaseous ammonia in dichloromethane), to deliver the title product as a white solid. Physical characteristics are as follows: MS (FAB, m/z) 699 [M+H]+. Exact Mass found: 699.4440.
Figure imgf000040_0001
Figure imgf000041_0001

Claims

CIAIMS 1. A peptide of the formula I
Y-D9-E10-F11-G12-H1 3-I 14-Z I wherein Y is
Figure imgf000042_0001
wherein R50 is
(a) chloro, (b) fluoro,
(c) methyl,
(d) ethyl,
(e) isopropyl,
(f) methyloxy, or (g) nitro; wherein j is 1 or 2 ; wherein the phenyl ring of formula Y is mono-substituted by R50 at the 2- or 3-posItion or is disubstituted by R50 at the 2,3-posltion, 2,5-positlon, 2,6-position, 3,5-position or 3,6-position; provided that when the phenyl ring of formula Y is mono-substituted with methyl, R50 is 2-methyl; wherein D9 is a divalent moiety of the formula XL3;
Figure imgf000042_0002
wherein E10-F11 is a divalent moiety of the formula XL6;
Figure imgf000042_0003
wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G12 is absent or a divalent moiety of the formula XL4;
Figure imgf000042_0004
wherein H13 is absent; wherein I14 is absent; wherein Z is
(a) -N(R10)(OR14), (b) -O-R10,
(c) -N(R4)R14, or
(d) C4-C8cyclic amino; wherein R is
(a) isopropyl, (b) isobutyl,
(c) phenylmethyl, or
(d) -(CH2)p-C3-C7cycloalkyl; wherein R1 is
(a) hydrogen, (b) C1-C5alkyl,
(c) aryl,
(d) C3-C7cycloalkyl,
(e) -Het,
(f) C1-C3alkoxy, or (g) C1-C3alkylthio; wherein R2 is
(a) hydrogen, or
(b) -CH(R3)R4; wherein R3 is (a) hydrogen,
(b) hydroxy,
(c) C1-C5alkyl,
(d) C3-C7cycloalkyl,
(e) aryl, (f) -Het,
(g) C1-C3alkoxy, or (h) C1-C3alkylthio; wherein R4 at each occurrence is the same or different and is (a) hydrogen, or (b) C1-C5alkyl; wherein R7 is
(a) hydrogen,
(b) C1-C5alkyl, (c) hydroxy,
(d) amino C1-C4alkyl-,
(e) guanidinyl C1-C3alkyl-,
(f) aryl,
(g) -Het,
(h) methylthio,
(i) -(CH2)p-C3-C7cycloalkyl, or (j) amino; wherein R8 is
(a) hydrogen,
(b) C1-C5alkyl,
(c) hydroxy,
(d) aryl,
(e) -Het,
(f) guanidinyl-C1-C3alkyl-, or
(g) -(CH2)p-C3-C7cycloalkyl; wherein R10 is
(a) hydrogen, or
(b) C1-C5alkyl; wherein R11 is -R or -R2; wherein R14 is
(a) C1-C10alkyl,
(b) -(CH2)n-aryl,
(c) -(CH2)n-Het,
(d) -(CH2)n+2-R18,
(e) -(CH2)n+2-R19,
(f) (hydroxy-C1-C8alkyl), or
(g) (C1-C3alkoxy)C1-C8alkyl; wherein R18 is
(a) amino,
(b) mono-, or di-C1-C3alkylamino,
(c) C4-C7cyclic amino, or
(d) C4-C7cycloalkylamino; wherein R19 is
(a) aryl,
(b) -Het,
(c) tri-C1-C3alkylamino,
(d) C3-C7cycloalkyl, (e) C2-C5alkenyl,
(f) C3-C7cycloalkenyl,
(g) hydroxy,
(h) C1-C3alkoxy,
(i) C1-C3alkanoyloxy,
(j) mercapto,
(k) C1-C3alkylthio,
(l) -COOH,
(m) -CO-O-C1-C6alkyl,
(n) -CO-O-CH2-(C1-C3alkyl)-N(C1-C3alkyl)2,
(o) -CO-NR22R25,
(p) guanidyl,
(q) cyano,
(r) N-cyanoguanidyl,
(s) cyanoamino, (t) (hydroxy-C2-C4alkyl)amino,
(u) di-(hydroxy-C2-C4alkyl)amino, or
(v) SO3H wherein R22 is
(a) hydrogen, or
(b) C1-C3alkyl; wherein R25 is
(a) hydrogen,
(b) C1-C3alkyl, or
(c) phenyl-C1-C3alkyl; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to two, inclusive; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following
(a) C1-C3alkyl,
(b) hydroxy,
(c) C1-C3alkoxy,
(d) halo,
(e) amino,
(f) mono- or di-C1-C3alkylamino,
(g) -CHO,
(h) -COOH, (i) COOR25, (j) CONHR25, (k) nitro, (1) mercapto, (m) C1-C3alkylthio,
(n) C1-C3alkylsulfinyl, (o) C1-C3alkylsulfonyl, (p) -N(R4)-C1-C3alkylsulfonyl, (q) SO3H, (r) SO2NH2,
(s) -CN, or (t) -CH2NH2; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following:
(i) C1-C6alkyl, (ii) hydroxy,
(iii) trifluoromethyl, (iv) C1-C4alkoxy,
(v) halo, (vi) aryl, (vii) aryl-C1-C4alkyl-,
(vlii) amino, or
(ix) mono- or di-C1-C4alkylamino; or a carboxy-, amino-, or other reactive group-protected form thereof; or a pharmaceutically acceptable acid addition salt thereof.
2. The peptide of claim 1 wherein R50 is 2-methyl; wherein D9 is His or a derivative thereof; wherein E10-F11 is LVA, CVA or a derivative thereof; wherein G12 is absent, Ile or a derivative thereof; wherein Z is
(a) -NH-OCH3, (b) 2-(Aminomethyl)pyridinyl, or
(c) -NH-CH2-CH(CH3)-CH3.
3. The peptide of claim 2 selected from the group consisting of: 2-Methylphenoxyacetyl-His-LVA-Ile-NHOCH3; 2-Methylphenoxyacetyl-His-LVA-Ile-Amp; 2-Methylphenoxyacetyl-His-LVA-Iba; and 2-Methylphenoxyacetyl-His-CVA-Ile-NHOCH3.
4. The peptide of claim 1 wherein R50 is
(a) 2-chloro,
(b) 3-chloro,
(c) 2-fluoro, (d) 3-fluoro,
(e) 2-ethyl,
(f) 2-isopropyl,
(g) 2,6-dimethyl, or (h) 2-methyloxy; wherein D9 is His or a derivative thereof; wherein E10-F11 is LVA or a derivative thereof; wherein G12 is Ile or a derivative thereof; wherein Z is
(a) -NH-OCH3, (b) 2-(Aminomethyl)pyridinyl, or
(c) -NH-CH2-CH(CH3)-CH3.
5. The peptide of claim 4 selected from the group consisting of:
3-Chlorophenoxyacetyl-His-LVA-Ile-NHOCH3; 2-Chlorophenoxyacetyl-His-LVA-Ile-NHOCH3;
2,6-Dimethylphenoxyacetyl-His-LVA-Ile-NHOCH3;
3-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3;
2-Methoxyphenoxyacetyl-His-LVA-Ile-NHOCH3;
2-Fluorophenoxyacetyl-His-LVA-Ile-NHOCH3; 2-Ethylphenoxyacetyl-His-LVA-Ile-NHOCH3; and
2-Isopropylphenoxyacetyl-His-LVA-Ile-NHOCH3.
PCT/US1989/001672 1988-05-03 1989-04-24 Renin inhibitory peptides containing a substituted phenoxyacetyle group WO1989010920A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18977788A 1988-05-03 1988-05-03
US189,777 1988-05-03

Publications (1)

Publication Number Publication Date
WO1989010920A1 true WO1989010920A1 (en) 1989-11-16

Family

ID=22698731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/001672 WO1989010920A1 (en) 1988-05-03 1989-04-24 Renin inhibitory peptides containing a substituted phenoxyacetyle group

Country Status (4)

Country Link
EP (1) EP0413750A1 (en)
JP (1) JPH03504127A (en)
AU (1) AU3570089A (en)
WO (1) WO1989010920A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393445A2 (en) * 1989-04-19 1990-10-24 Bayer Ag Use of peptide renin inhibitors as an agent against retrovirus
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
EP0813868A2 (en) * 1990-11-19 1997-12-29 Monsanto Company Retroviral protease inhibitors
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5679688A (en) * 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
MXPA93002392A (en) 1992-03-11 2005-02-04 Narhex Ltd Amine derivatives of oxo- and hydroxy-substitued hydrocarbons.
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156322A2 (en) * 1984-03-27 1985-10-02 Merck & Co. Inc. Renin inhibitors containing peptide isosteres
EP0173481A2 (en) * 1984-08-06 1986-03-05 The Upjohn Company Peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156322A2 (en) * 1984-03-27 1985-10-02 Merck & Co. Inc. Renin inhibitors containing peptide isosteres
EP0173481A2 (en) * 1984-08-06 1986-03-05 The Upjohn Company Peptides

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393445A3 (en) * 1989-04-19 1991-02-06 Bayer Ag Use of peptide renin inhibitors as an agent against retrovirus
EP0393445A2 (en) * 1989-04-19 1990-10-24 Bayer Ag Use of peptide renin inhibitors as an agent against retrovirus
EP0813868A3 (en) * 1990-11-19 1998-03-18 Monsanto Company Retroviral protease inhibitors
EP0813867A3 (en) * 1990-11-19 1998-04-01 Monsanto Company Retroviral protease inhibitors
EP0813868A2 (en) * 1990-11-19 1997-12-29 Monsanto Company Retroviral protease inhibitors
EP0813867A2 (en) * 1990-11-19 1997-12-29 Monsanto Company Retroviral protease inhibitors
US5804552A (en) * 1991-07-23 1998-09-08 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5760036A (en) * 1992-07-20 1998-06-02 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5776933A (en) * 1992-07-20 1998-07-07 E. R. Squibb & Sons, Inc. Method of inhibiting protease
US6730671B2 (en) 1999-03-02 2004-05-04 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathespin S
US6608057B2 (en) 1999-03-02 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin S
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6982272B2 (en) 1999-09-13 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7056915B2 (en) 1999-09-13 2006-06-06 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7265132B2 (en) 1999-09-13 2007-09-04 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7279472B2 (en) 1999-09-13 2007-10-09 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6858623B2 (en) 2000-09-08 2005-02-22 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases

Also Published As

Publication number Publication date
EP0413750A1 (en) 1991-02-27
AU3570089A (en) 1989-11-29
JPH03504127A (en) 1991-09-12

Similar Documents

Publication Publication Date Title
US5132400A (en) Peptides containing a (1-amino-2-hydroxy-2-heterocyclic)ethyl moiety
WO1992003472A1 (en) Peptides containing amino-polyols as transition-state mimics
US4663310A (en) Renin inhibitors containing 2-substituted statine
EP0483271B1 (en) Peptides containing diamino-glycols as transition-state mimics
WO1989010920A1 (en) Renin inhibitory peptides containing a substituted phenoxyacetyle group
WO1988002374A2 (en) Renin inhibitory peptides having novel c-terminal moieties
WO1989004833A1 (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
US4839357A (en) Renin inhibitors containing phenylalanyl-histidine replacements
US5049548A (en) Renin-inhibitory di-, tri-, and tetrapeptides
WO1990012804A2 (en) Peptides having novel polar n-terminal groups
EP0312157A2 (en) Tetrapeptide renin inhibitors having a novel c-terminal amino acid
EP0278158A2 (en) Renin inhibitors containing phenylalanyl-histidine replacements
WO1989001488A1 (en) Renin inhibiting peptides with nonpeptide linkages
WO1990002137A1 (en) Renin inhibitory peptides containing suleptanic acid or derivatives thereof
AU617740C (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
AU617740B2 (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
US5006511A (en) Di- or tripeptide renin inhibitors containing lactam conformational restriction in achpa
US5114925A (en) Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5039664A (en) Renin inhibitors containing phenylalanyl-histidine replacements
WO1990003389A1 (en) Renin inhibitory peptides containing maleamide substituents
WO1989000161A1 (en) Malic acid derivative containing renin inhibiting peptides
WO1988004664A2 (en) Renin-inhibitory peptides having an epoxide or glycol moiety
WO1991007430A1 (en) Peptides containing cyclic tripeptides
US5037807A (en) Renin inhibitors containing phenylalanyl-histidine replacements
EP0312283A2 (en) Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1989905893

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI HU JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1989905893

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989905893

Country of ref document: EP